Research

June 21, 2020

Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 

By VUMC News and Communications
June 18, 2020

Probing DNA damage repair

After discovering a new mechanism for DNA damage repair last year, Vanderbilt biochemists now provide direct evidence for how it works.

By Leigh MacMillan
June 18, 2020

Studying cells in reduced dimensions

Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data.

By Bill Snyder
June 18, 2020

All of Us program launches cloud-based research platform

On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench.

By Paul Govern
June 18, 2020

Bhave, Grome receive awards at Research Forum

Gautam (Jay) Bhave, MD, PhD, assistant professor of Medicine and Cell & Developmental Biology, is the recipient of the 2020 Grant W. Liddle Award for “exemplary leadership in the promotion of scientific research” at Vanderbilt University Medical Center.

By Bill Snyder
June 12, 2020

Robotic technology speeds arrhythmia gene classification

Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.

By Leigh MacMillan
June 10, 2020

C. diff captures blood cell cofactor to build defensive shield

Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.
By Leigh MacMillan
June 9, 2020

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
By Bill Snyder
June 9, 2020

Staph’s activation of blood clotting

Staph bacteria may change the factor they use to activate blood clotting — to evade the immune response — a new study suggests.
By Leigh MacMillan
June 8, 2020

When rankings are unfounded

There are many good reasons to survey anesthesiology patient satisfaction but ranking individual clinicians isn’t one of them, the authors of a new study conclude.
By Paul Govern
June 4, 2020

Protecting the injured kidney

Leslie Gewin and colleagues have upended conventional dogma about Wnt/beta-catenin signaling in the kidney, finding that it protects against chronic kidney disease rather than promoting it.
By Leigh MacMillan
June 4, 2020

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.
By Bill Snyder
June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
By Bill Snyder
1 … 66 67 68 69 70 … 125